Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

IL-2 and CD40L can establish and sustain a human B cell-mediated immune regulatory network.

Created on 24 Oct 2026

Authors

Laurie Baert, Adrien Caffiers, Agnes Yang, Sae Rome Choi, Suman Bose, SangKon Oh

Published in

bioRxiv : the preprint server for biology. Oct 18, 2026. Epub Oct 18, 2026.

Abstract

B cells can control inflammation, but the factors governing B cell-mediated immune regulatory network remain unclear. We report that IL-2/CD40L enable class-switched memory (CSM) B cells to acquire an immunosuppressive phenotype characterized by the expression of surface TIGIT as well as multiple other inhibitory receptors (PD-1, LAG-3, GITR, CD39, and CTLA-4) and soluble molecules (IL-10, granzyme B, and IL-35). TIGIT + CSM B cells expressing functional CCR9 exhibit significant defects in total immunoglobulin secretion, while preserving IgA2 secretion. Furthermore, IL-2/CD40L-induced ex vivo -generated TIGIT + CSM B cells suppress human T cell-mediated inflammation in a xenogeneic mouse model of acute graft-versus-host disease, while promoting IL-10-producing regulatory T cell (Treg) response. These findings identify IL-2/CD40L as key drivers of a B cell-mediated immune regulatory network, especially by generating TIGIT + CSM B cells that can further promote Treg response. This study supports the development of TIGIT + B cell-based therapy models for inflammatory diseases.
IL-2/CD40L can generate and maintain immunosuppressive TIGIT + B cells in humans. TIGIT + B cells expressing CCR9 have defects in antibody secretion, but not IgA2. TIGIT + B cells suppress inflammation, while promoting Treg response in vivo . IL-2/CD40L can thus build a robust B cell-mediated immune regulatory network.

PMID:
42920441
Bibliographic data and abstract were imported from PubMed on 24 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 14
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement